Imatinib Plus Steroids Induces Complete Remissions And ... - PubMed

Clipboard, Search History, and several other advanced features are temporarily unavailable. Skip to main page content

The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation Search: Search Advanced Clipboard Save Email Send to

• Clipboard
• My Bibliography
• Collections
• Citation manager

Display options Display options Format Abstract PubMed PMID

Save citation to file

Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel

Email citation

Email address has not been verified. Go to My NCBI account settings to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel

Add to Collections

• Create a new collection
• Add to an existing collection

Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error Please try again Add Cancel

Add to My Bibliography

• My Bibliography

Unable to load your delegates due to an error Please try again Add Cancel

Your saved search

Name of saved search: Search terms: Test search terms Would you like email updates of new search results? Saved Search Alert Radio Buttons

• Yes
• No

Email: (change) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel

Create a file for external citation management software

Create file Cancel

Your RSS Feed

Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy

Full text links

Silverchair Information Systems Elsevier Science Full text links

Actions

CiteCollectionsAdd to Collections

• Create a new collection
• Add to an existing collection

Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an errorPlease try again Add Cancel PermalinkPermalinkCopyDisplay options Display options Format AbstractPubMedPMID

Page navigation

• Title & authors
• Abstract
• Publication types
• MeSH terms
• Substances
• LinkOut - more resources

Title & authors Abstract Publication types MeSH terms Substances LinkOut - more resources Full text links CiteDisplay options Display options Format AbstractPubMedPMID

Abstract

Thirty elderly (> 60 years) Philadelphia chromosome-positive (Ph(+)) patients with acute lymphoblastic leukemia (ALL) received imatinib, 800 mg daily, associated to steroids without further chemotherapy as frontline treatment. Median age was 69 years (range, 61-83 years). Twenty-nine patients were evaluable for response and all of them obtained a hematologic complete remission, with a median BCR-ABL reduction of 2.9 and 2.0 logs in p190(+) and p210(+) cases, respectively. Most of the induction treatment did not require admission of the patients. No major toxicities occurred and the treatment was well tolerated. Median survival from diagnosis was 20 months. This study shows that elderly Ph(+) patients with ALL-often considered eligible only for palliative treatment strategies-may benefit from an imatinib-steroids protocol, which does not require chemotherapy nor a long hospitalization, is feasible, highly active, and associated with a good quality of life.

PubMed Disclaimer

Publication types

• Clinical Trial Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Comparative Study Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Multicenter Study Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Research Support, Non-U.S. Gov't Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search

MeSH terms

• Aged Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Aged, 80 and over Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Antineoplastic Combined Chemotherapy Protocols / administration & dosage* Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Antineoplastic Combined Chemotherapy Protocols / adverse effects Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Benzamides Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Disease-Free Survival Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Female Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Follow-Up Studies Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Fusion Proteins, bcr-abl / genetics Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Humans Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Imatinib Mesylate Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Male Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Middle Aged Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Piperazines / administration & dosage Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Piperazines / adverse effects Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy* Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Pyrimidines / administration & dosage Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Pyrimidines / adverse effects Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Remission Induction Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Steroids / administration & dosage Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Steroids / adverse effects Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Survival Rate Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search

Substances

• Benzamides Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Piperazines Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Pyrimidines Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Steroids Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Imatinib Mesylate Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Fusion Proteins, bcr-abl Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search

LinkOut - more resources

• Full Text Sources

  • Elsevier Science
  • Silverchair Information Systems

• Medical

  • ClinicalTrials.gov

• Miscellaneous

  • NCI CPTAC Assay Portal

Full text links [x] Silverchair Information Systems Elsevier Science [x] Cite Copy Download .nbib .nbib Format: AMA APA MLA NLM Send To

• Clipboard
• Email
• Save
• My Bibliography
• Collections
• Citation Manager

[x]

NCBI Literature Resources

MeSH PMC Bookshelf Disclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.